S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
BREAKING: Tiny biotech successfully treats blindness (Ad)
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
BREAKING: Tiny biotech successfully treats blindness (Ad)
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
Bear market expert makes new prediction (Ad)
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

$40.44
+1.23 (+3.14%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$39.14
$40.57
50-Day Range
$38.82
$54.59
52-Week Range
$37.59
$79.50
Volume
143,696 shs
Average Volume
189,486 shs
Market Capitalization
$844.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.60

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
69.6% Upside
$68.60 Price Target
Short Interest
Bearish
4.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.11
Upright™ Environmental Score
News Sentiment
1.07mentions of Enanta Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($7.36) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

188th out of 996 stocks

Pharmaceutical Preparations Industry

75th out of 484 stocks


ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Down 4.5%
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Expert Ratings for Enanta Pharma
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
SVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Earnings Outlook For Enanta Pharmaceuticals
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
2/07/2023
Today
4/02/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$68.60
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$49.00
Forecasted Upside/Downside
+69.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-121,750,000.00
Net Margins
-146.93%
Pretax Margin
-147.46%

Debt

Sales & Book Value

Annual Sales
$86.16 million
Book Value
$15.51 per share

Miscellaneous

Free Float
18,233,000
Market Cap
$844.79 million
Optionable
Optionable
Beta
0.40

Key Executives

  • Jay R. LulyJay R. Luly
    President, Chief Executive Officer & Director
  • Paul J. Mellett
    CFO & Senior VP-Finance & Administration
  • Yat Sun Or
    CSO, Senior Vice President-Research & Development
  • Scott T. Rottinghaus
    Chief Medical Officer & Senior Vice President
  • Nathaniel S. Gardiner
    Secretary, Senior Vice President & General Counsel













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2023?

9 Wall Street analysts have issued 1 year price objectives for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they anticipate the company's stock price to reach $68.60 in the next year. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2023?

Enanta Pharmaceuticals' stock was trading at $46.52 at the start of the year. Since then, ENTA stock has decreased by 13.1% and is now trading at $40.44.
View the best growth stocks for 2023 here
.

Are investors shorting Enanta Pharmaceuticals?

Enanta Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 900,100 shares, an increase of 20.0% from the February 28th total of 750,300 shares. Based on an average daily trading volume, of 168,700 shares, the days-to-cover ratio is currently 5.3 days. Currently, 4.7% of the shares of the stock are sold short.
View Enanta Pharmaceuticals' Short Interest
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Tuesday, February, 7th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.52) by $0.13. The biotechnology company earned $23.60 million during the quarter, compared to the consensus estimate of $22.48 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 36.59% and a negative net margin of 146.93%. The company's quarterly revenue was down 14.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.48) EPS.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $40.44.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $844.79 million and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.82) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 4/2/2023 by MarketBeat.com Staff